최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0842716 (2004-05-10) |
등록번호 | US7875293 (2011-01-10) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 82 인용 특허 : 351 |
A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is pro
A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.
What is claimed is: 1. An implantable glucose sensor having a biointerface membrane comprising:a first domain comprising a nonresorbable solid portion comprising a plurality of interconnected cavities having a pore size greater than about 30 μm, as determined by a bubble point test measurement, wher
What is claimed is: 1. An implantable glucose sensor having a biointerface membrane comprising:a first domain comprising a nonresorbable solid portion comprising a plurality of interconnected cavities having a pore size greater than about 30 μm, as determined by a bubble point test measurement, wherein the solid portion is adapted to support a tissue ingrowth in vivo;a second domain located adjacent to the first domain, wherein the second domain is impermeable to cells or cell processes and is configured to allow a passage of glucose therethrough; anda bioactive agent incorporated into the biointerface membrane, wherein the bioactive agent is capable of modifying a tissue response in such a way that sleep period effects on the implantable glucose sensor are reduced, wherein the bioactive agent is configured to be released from the first domain and/or the second domain.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.